poisar

Stock

Alto Neuroscience Inc. ANRO

$31.33-3.00%

Overview

ANRO market data

Price History

ANRO price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.50
Diluted earnings per share over the trailing twelve months.
Beta
1.13
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-4,374.8%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.02 – $29.70
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1.1B · P/B 3.66.

Company News

8 captured
Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $26Benzinga · Aug 13, 2026, 12:52 PM
BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37Benzinga · Aug 13, 2026, 10:12 AM
Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) EstimateBenzinga · Aug 12, 2026, 8:19 PM
8-K filing — Alto Neuroscience, Inc. (ANRO)SEC EDGAR · Aug 12, 2026, 8:14 PM
Alto Neuroscience Prices ~$100M Offering Of 3.776M Common Shares At $26.48/ShareBenzinga · Jul 13, 2026, 11:48 AM
Alto Neuroscience Intends To Accelerate And Expand Clinical Development Of ALTO-207, Including An Additional Planned Phase 3 Trial As Monotherapy For Treatment-Resistant DepressionBenzinga · Jul 13, 2026, 11:46 AM
Alto Neuroscience Publishes Trial Of Dopamine Agonist Pramipexole With Mood Disorders And Clinically Significant Anhedonia In Nature MediceBenzinga · Jun 15, 2026, 12:20 PM
Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36Benzinga · May 18, 2026, 5:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock